NEW YORK – Myriad Genetics announced that it will file a supplementary premarket approval application with the US Food and Drug Administration for its BRACAnalysis CDx to be used to identify which metastatic, castration-resistant prostate cancer patients have germline BRCA mutations and may benefit from treatment with olaparib (AstraZeneca and Merck’s Lynparza).